Company: TVRD
Filing Date: 2025-01-24
Form Type: CORRESP
Source: 0001104659-25-006051
Chunk: 6

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-24
Form: CORRESP
Chunk 6
---
 have already 
 received a deficiency letter from Nasdaq regarding your non-compliance with this listing requirement and disclose the status of your efforts 
 to regain compliance with the requirement.                                                                                                   |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 232 and 233 of the Amended
Registration Statement to disclose the receipt of the deficiency letter from Nasdaq and the status of the Company’s efforts to regain
compliance.

| 16. | In the second paragraph, you include disclosure regarding the number of shares of your common stock                                      
 expected to be available for future issuance following the issuance of your shares in the Merger. Please also clarify how many of these  
 shares you expect will be reserved for future issuance (e.g., pursuant to your equity compensation plans, for issuance upon the exercise 
 of options, etc.).                                                                                                                       |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 240 of the Amended Registration
Statement to state the number of shares expected to be reserved for future issuance.

| 17. | In the last paragraph, you state that the issuance of additional shares of your common stock could                                         
 have dilutive effects. To the extent applicable, please also disclose any potential anti-takeover or other effects of the Authorized Share 
 Proposal.                                                                                                                                  |

Response:The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 240 of the Amended
Registration Statement to add potential anti-takeover effects of the Authorized Share Proposal.

| 18. | To the extent applicable, please also include discussion here of the Tvardi support agreements and 
 the lock-up agreements entered into in connection with the Merger.                                 |

Response:The Company acknowledges the Staff’s comment and has revised the disclosure on page 385 of the Amended Registration
Statement to discuss the Tvardi support agreements and lock-up agreements entered into in connection with the Merger.

MINTZ

| 19. | We note your statement that the registration rights set forth in Tvardi's amended and restated investors'                              
 rights agreement will continue following completion of the Merger. Please disclose the number of shares subject to registration rights 
 and briefly describe the material terms of such registration rights.                                                                   |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 387 of the Amended Registration
Statement to clarify that all of Tvardi’s investor agreements, including the registration rights in the investors’ rights
agreement will